CMS Decision De-Facto Denial of All Medicare Patient Access to Aduhelm: Biogen

Biogen issued a statement on April 7 lashing out at US authorities’ decision finalized on the day to limit Medicare coverage for its Alzheimer’s drug Aduhelm (aducanumab) to patients participating in certain clinical trials. The Centers for Medicare and Medicaid...read more